JP2007277128A - Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same - Google Patents

Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same Download PDF

Info

Publication number
JP2007277128A
JP2007277128A JP2006103874A JP2006103874A JP2007277128A JP 2007277128 A JP2007277128 A JP 2007277128A JP 2006103874 A JP2006103874 A JP 2006103874A JP 2006103874 A JP2006103874 A JP 2006103874A JP 2007277128 A JP2007277128 A JP 2007277128A
Authority
JP
Japan
Prior art keywords
powder
lifestyle
obesity
per day
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006103874A
Other languages
Japanese (ja)
Inventor
Yutaka Araki
裕 荒木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2006103874A priority Critical patent/JP2007277128A/en
Publication of JP2007277128A publication Critical patent/JP2007277128A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To establish treatment method for obesity, diabetes and hyperlipidemia, and to provide pharmaceuticals effective to obesity, diabetes and hyperlipidemia. <P>SOLUTION: The invention relates to the method comprising administration of either of Bofu-tsushousan (R), Magnoliae Cortex powder and Curcuma zedoaria powder, and powders of Astragali Radix, Elsholtzia ciliata, Eleutherococcus senticosus, Cassia tora, Citrus aurantium, Antidesma pentandrum and Actinidia polygama. The amount of administration of the Bofu-tsushousan (R) per day follows the amount defined by Chinese medicine formulation per day, and other ingredients are each defined as 0.5-25 wt.% of the Bofu-tsushousan (R). The administration is carried out three times per day at before every meal or two times per day at before morning and evening meal by equally dividing the amount of administration per day into tree or two. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は生活習慣病の予防・改善方法及び予防・改善剤に関し、特に肥満症、糖尿病、高脂血症等の生活習慣病の予防、治療法およびこれに使用される医薬に関する。   The present invention relates to a method for preventing / ameliorating lifestyle-related diseases and a preventive / ameliorating agent, and more particularly, to a method for preventing and treating lifestyle-related diseases such as obesity, diabetes, hyperlipidemia and the like and a medicine used therefor.

肥満は、糖尿病、心血管疾患などの生活習慣病の元凶であるメタボリックシンドロームの引き金であるとされ、現代社会において大きな問題となっている。肥満を解消するためダイエットによるカロリー制限や運動等いろいろな試みがなされているが、いずれも長続きせず、失敗に終わることが多いのが現状である。   Obesity is considered to be a trigger for metabolic syndrome, which is the cause of lifestyle-related diseases such as diabetes and cardiovascular diseases, and has become a major problem in modern society. Various attempts such as dietary calorie restriction and exercise have been made to eliminate obesity, but none of them are long-lasting and often fail.

ところで、漢方の防風通聖散は、後述するように種々の生薬成分よりなるものであるが、成分中、ボウフウ、ケイガイ、マオウは強い発汗作用を示し、ケイガイ、マオウは利尿を促進する。ハッカは軽度の発汗作用を有し、又、健胃作用をも有する。レンギョウ、サンシシ、オウゴン、生セッコウは、強い消炎、解熱作用を持ち、レンギョウは軽度の発汗作用により熱の放散を強め、強心、利尿に働く。サンシシは利胆に働き、オウゴンも利胆、利尿に働き、解毒の効果を強める。生セッコウは血管透過性亢進の抑制に働く。ダイオウは、ボウショウとともに腸管内の糞便を写下によって除き、又、利胆、利尿作用により解毒を補助する。カッセキは利尿作用を有する。ビャクジュツは消化吸収を強め、消化管内の水分を血中に引込み、利尿する。トウキ、ビャクジュツは、滋養強壮作用を有し、体を栄養、滋潤する。   By the way, Chinese herbal breezes are composed of various herbal ingredients as will be described later. In the ingredients, Bowfu, Keigai and Maou show a strong sweating action, and Keigai and Maou promote diuresis. Mentha has a mild sweating effect and also has a healthy stomach effect. Forsythia, Sanshishi, Ogon, and raw gypsum have strong anti-inflammatory and antipyretic effects. Forsythia enhances heat dissipation by mild sweating, and works for incentives and diuresis. Sanshishi works daringly, and Ogon works daringly and diuretics, strengthening the detoxification effect. Raw gypsum works to suppress increased vascular permeability. Diou removes feces in the intestinal tract together with bowshade by copying, and also assists detoxification by bile and diuretic action. Casseki has a diuretic effect. Sandalwood enhances digestion and absorption, drawing water from the digestive tract into the blood and diuresis. Toki and peanut have nourishing tonic, nourishing and nourishing the body.

以上のような作用により、防風通聖散は、代謝産物の排泄や脂肪分の減少に有効であるとされ、主として肥満の治療に用いられてきた。しかしながら、後記するように、それ単独では治療効果はあまり期待できない。   Due to the effects described above, Fengtsu Sansho is considered effective for excretion of metabolites and reduction of fat content, and has been mainly used for the treatment of obesity. However, as will be described later, the therapeutic effect by itself cannot be expected so much.

他方、本件発明者は、防風通聖散の坑肥満作用を向上させるために、車前子及びモロヘイヤを併用するようにした抗肥満剤を完成し、出願するに至った(特許文献1)。   On the other hand, the present inventor has completed and filed an application for an anti-obesity agent that uses a vehicle anterior element and Morohaya in order to improve the anti-obesity effect of Fukatsu Tsusho-san (Patent Document 1).

特開平11−130689号公報JP-A-11-130689

前述のように、防風通聖散が抗肥満作用を有することは知られているが、これ単独では、その効果は極めて弱く、本発明者による肥満及びこれに伴う糖尿病、肝臓機能障害、高血圧の患者への投与結果によれば、有効と認められたのは約1割に過ぎなかった。しかも治療に長期間を要することから、患者に多大の忍耐や精神的負担を課すこととなり、殆どの患者は半年以内に挫折し、治療を行うことができなかった。   As mentioned above, it is known that Fengtsu Sansho has an anti-obesity effect, but by itself, its effect is extremely weak, and obesity by the present inventor and associated diabetes, liver dysfunction, hypertension. According to the results of administration to patients, only about 10% was recognized as effective. Moreover, since treatment requires a long period of time, it imposes a great deal of patience and mental burden on the patient, and most patients have failed within six months and cannot be treated.

特に女性患者に多い、腰痛、肩凝り、めまい、膝関節痛、高血圧等、肥満に起因するとみられる慢性疾患を抱える患者は、それまでにいろいろな薬剤を長期にわたり投与されていることから、病状の改善が容易でなかった。   Patients with chronic diseases that are likely to be caused by obesity, such as back pain, stiff shoulders, dizziness, knee joint pain, and high blood pressure, which are particularly common among female patients, have been treated with various drugs for a long time. It was not easy to improve.

本発明はかかる状況においてなされたもので、本件発明者の開発に係る抗肥満剤(特開平11−130689号公報)をさらに改良し、防風通聖散の抗肥満作用を飛躍的に向上させるだけでなく、その単独投与の場合に比べ、極めて短期間に優れた高脂血症、糖尿病などの生活習慣病を予防し改善できるようにした生活習慣病の予防・改善方法及び予防・改善剤を提供することを課題とする。   The present invention has been made in such a situation, and further improves the anti-obesity agent (Japanese Patent Laid-Open No. 11-130689) related to the development of the present inventor and dramatically improves the anti-obesity effect of Fukatsutsu Seisaku. In addition, the prevention / improvement method and preventive / ameliorating agent for lifestyle-related diseases that can prevent and ameliorate lifestyle-related diseases such as hyperlipidemia and diabetes that are superior in a very short period of time compared to the case of single administration. The issue is to provide.

本発明に係る生活習慣病の予防・改善方法は、防風通聖散、コウボク末とガジュツ末のいずれか、オウギ末、コウジュ末、ゴカジン末、ケツメイシ末、キジュツ末、ヒハツ末およびモクテンリョウ末を投与することを特徴とする。   The method for preventing / ameliorating lifestyle-related diseases according to the present invention comprises administering Fufutsu Seisaku, Kokuboku powder and Gajutsu powder, Ogi powder, Koju powder, Gokajin powder, Ketsumeishi powder, Kijutsu powder, Hihatsu powder and Mokten Ryo powder. It is characterized by doing.

防風通聖散に、色々なハーブ、詳しくはコウボク末とガジュツ末のいずれか、オウギ末、コウジュ末、ゴカジン末、ケツメイシ末、キジュツ末、ヒハツ末およびモクテンリョウ末を組み合わせることにより、血管を拡張したり、筋肉の働きを高め、胃腸の動きを調整し、発汗、利尿効果など様々な身体機能の向上を計り、厳しいダイエットや運動を行うことなく生活習慣病の改善が出来る。   Expanding blood vessels by combining various herbs, in particular, one of Koboku and Gakutsu, Ogi, Koji, Gokajin, Ketsumeishi, Kijitsu, Hihatsu and Mokten Ryou Or improve muscle function, adjust gastrointestinal movement, improve various physical functions such as sweating and diuretic effect, and improve lifestyle diseases without strict diet and exercise.

本発明は、防風通聖散に、コウボク又はガジュツいずれか、オウギ、コウジュ、ゴカジン、ケツメイシ、キジュツ、ヒハツ、モクテンリョウの粉末を併用することにより、治療効果を飛躍的に向上し得るものである。   According to the present invention, the therapeutic effect can be drastically improved by using a combination of either Koboku or Gajutsu, Ogi, Kojyu, Gokajin, Ketsumeishi, Kizuttsu, Hibatsu, and Mokten Ryo in combination with Fufutsu Seisaku.

次に、本発明で使用される防風通聖散以外の成分について説明すると、コウボクは、アドレナリン増強作用、神経節遮断作用、坑ピロカルピン作用が認められている。腸管に対する軽度の緩下作用や消化管粘膜への刺激作用を有することにより、整腸剤や消化剤として用いられる。また、利尿剤としても使用される。   Next, a description will be given of components other than the windproof sansho used in the present invention. As for Koboku, adrenaline enhancing action, ganglion blocking action, and antipilocarpine action are recognized. It has a mild laxative effect on the intestinal tract and a stimulating effect on the gastrointestinal mucosa, so that it can be used as an intestinal or digestive agent. It is also used as a diuretic.

ガジュツは、本発明に係る医薬としてコウボクを配合したものを患者に投与して、患者が下痢症状を訴えた場合に、コウボクに代えて使用するものであっる。   Gajutsu is used in place of Kokuboku when a compound containing Koboku as a medicine according to the present invention is administered to a patient and the patient complains of diarrhea.

オオギは、イソフラボノイド、数種のアミノ酸、葉酸などを含むため、血圧降下作用を有し、血管拡張により皮膚の血液循環と栄養状態を改善する。利尿作用はかなり顕著である。オオギの強壮作用は、性ホルモン様作用と中枢神経系の興奮作用に関連するものと考えられている。   Since ogi contains isoflavonoids, several amino acids, folic acid, etc., it has a blood pressure lowering effect and improves blood circulation and nutritional status of the skin by vasodilation. The diuretic effect is quite pronounced. Ogi's tonicity is thought to be related to sex hormone-like effects and central nervous system excitability.

コウジュは、発汗、利尿薬として用いられたり、全身浮腫などの治療にも利用されている。   Koju is used for sweating, diuretics, and for treating systemic edema.

ゴカジンは、血管を拡張して血圧を降下させ、中枢神経に作用して鎮静する作用が認められる。人参よりすぐれたアダプトゲン様の作用によって筋肉の抵抗力を増加させ、筋肉内ATP産生を増加させる。また、脳内血流を高め、脳内ホルモンの分泌を促す働きがある。   Gokadine is found to dilate blood vessels to lower blood pressure and to act on the central nerves to sedate. Increases muscle resistance and increases intramuscular ATP production by adaptogen-like action superior to ginseng. In addition, it increases blood flow in the brain and promotes the secretion of hormones in the brain.

キジュツは、胆汁分泌促進、血清コレステロール低下、鎮静などの作用が知られている。蠕動リズムを調整する働きもあるため消化不良などの治療にも用いられる。   Jujutsu is known to have actions such as promoting bile secretion, lowering serum cholesterol, and sedation. It can also be used for the treatment of indigestion because of its ability to adjust peristaltic rhythm.

ケツメイシは、降圧、利尿作用、坑血脂作用、胃液分泌促進作用などのあることが報告されている。   Ketsumeishi has been reported to have antihypertensive, diuretic, antilipidemic, and gastric juice secretion promoting effects.

モクテンリョウには、唾液分泌促進作用、平滑筋の抑制作用などがみられ、鎮痛、リュウマチ、神経痛の治療や強壮剤として用いられる。   Mocten Ryo has a salivary secretion promoting action, a smooth muscle inhibiting action, etc., and is used as a treatment or tonic for analgesia, rheumatism, neuralgia.

ヒハツは、現在アメリカで、血流改善による冷え性に有効であることや脂肪燃焼作用があるということで、肥満に悩む人達が多く服用している。   Hihatsu is currently used in the United States by many people who suffer from obesity because it is effective for cooling by improving blood flow and has a fat burning effect.

本発明では、防風通聖散、コウボク又はガジュツのいずれか、オウギ、コウジュ、ゴカジン、ケツメイシ、キジュツ、ヒハツ及びモクテンリョウ(以下、防風通聖散以外の有効成分を、コウボク等とまとめて略称することがある)を含有してなる坑生活習慣病薬剤を投与することにより、生活習慣病を予防し改善することができる。コウボクとガジュツのいずれかを用いるのは、コウボクを用いた場合、薬剤を投与された患者が下痢状態を訴えたとき、コウボクに代えてガジュツを使用するのがよいためである。   In the present invention, any one of Fufutsu Seisaku, Koboku or Gajutsu, Ogi, Koju, Gokajin, Ketsumeishi, Kijutsu, Hibatsu and Mokten Ryo (hereinafter, the active ingredients other than Fufutsu Seisaku are collectively abbreviated as Koboku etc.) Lifestyle-related diseases can be prevented and ameliorated by administering an anti-lifestyle-related disease drug comprising The reason why either Kokuboku or Gakutsu is used is that, when Kokuboku is used, when a patient who has been administered a drug complains of diarrhea, it is better to use Gakutsu instead of Kokuboku.

防風通聖散は、成書(例えば厚生省薬務局監修、日薬連漢方専門委員会編集、薬業時報社発行、一般用漢方処方の手引き)によれば、その成分及び分量は、トウキ1.2(重量部、以下同じ)、シャクヤク1.2、センキュウ1.2、サンシシ1.2、レンギョウ1.2、ハッカ1.2、ショウキョウ1.2、ケイガイ1.2、ボウフウ1.2、マオウ1.2、ダイオウ1.5、ボウショウ1.5、ビャクジュツ2.0、キキョウ2.0、オウゴン2.0、カンゾウ2.0、セッコウ2〜3、カッセキ3〜5とされており、原則として、これを、その10倍量部(従って280〜350)の湯で、1/2容量となるまで濃縮し、固形分を除いたもの(湯すなわちエキス)が用いられる。   According to a written book (e.g., supervised by the Ministry of Health and Welfare Pharmaceutical Affairs Bureau, edited by the National Pharmacopoeia Specialist Committee, published by the Pharmaceutical Industry Journal, a guide to general-purpose Kampo prescriptions), the ingredients and amounts are as follows. .2 (parts by weight, the same applies hereinafter), Peonies 1.2, Senkyu 1.2, Sunshi 1.2, Forsythia 1.2, Hakka 1.2, Showa 1.2, Keiguy 1.2, Bow Fu 1.2 , Maow 1.2, Daio 1.5, Bow Show 1.5, Sandalwood 2.0, Kyaku 2.0, Ogon 2.0, Licorice 2.0, Gypsum 2-3, Kasseki 3-5, In principle, this is concentrated in 10 times its part (thus 280-350) of hot water until it becomes 1/2 volume and the solid content is removed (hot water or extract).

なお、成書によっては、上記成分中、ビャクジュツを含まないもの(例えば大塚敬節・矢数道明監集、医道の日本社発行、経験漢方処方分量集)や、オウゴンを含まないもの(例えば大阪読売新聞社編、浪速社発行、続漢方あれこれ)や、上記分量中、1.2をすべて1.5としているもの(例えば西岡一夫、高橋真太郎共著、浪速社発行、明解漢方処方)など、成分や成分比が多少異なるものもある。   Depending on the book, the above ingredients may not contain peanuts (eg, Takatsuka Otsuka and Michiaki Yazume, published by Nippon Shokudo Co., Ltd.) Ingredients such as Yomiuri Shimbun, published by Naniwasha, and follow-up Chinese medicines, and those in which 1.2 is set to 1.5 (for example, co-authored by Kazuo Nishioka and Shintaro Takahashi, published by Naniwasha, Myoken Kampo Prescription) Some have slightly different component ratios.

さらに、エキスの作り方として、ボウショウ以外の上記各成分に水400量部を加え、200量部まで煎じ、かすを除き、次いでボウショウを加えるとしているもの(例えば久保道徳、森山健三共著、保育社発行、和漢薬ハンドブック)のように、作り方が多少異なるものもある。   Furthermore, as a method of making an extract, 400 parts by weight of water is added to each of the above components other than bow show, decoction is made up to 200 parts, debris is added, and then bow show is added (for example, published by Michinori Kubo, Kenzo Moriyama, published by Yoikusha) Some handbooks are slightly different, as in the Japanese and Chinese medicine handbook).

本発明において、防風通聖散とは、漢方生薬調査会により定められた「漢方製剤の基本的取扱い方針」に規定されるように、このような現在繁用されている漢方関係の成書に記載されている処方、従って上記のような成分や成分比の多少異なるものを含む、いわゆる漢方処方(生薬配合物)やこれらの漢方処方から得られるエキスをも包含する。しかし、エキスは、保存や服用の困難さの点からも適当とは言えないし、さらに、漢方処方となれば、患者は、このような煎じ薬をその都度、作らねばならず、患者に多大の負担を与えることになり、好ましいものではない。   In the present invention, Fufutsu Seisaku is a book related to Chinese medicine that is currently in common use, as stipulated in the “Basic Handling Policy of Kampo Formulations” established by the Kampo Medicine Research Committee. Also included are so-called Chinese herbal formulas (herbal medicine formulations) and extracts obtained from these Chinese herbal formulas, including the described formulas, and therefore those with somewhat different ingredients and component ratios as described above. However, the extract is not appropriate in terms of storage and administration difficulties, and if it is a Kampo prescription, the patient must make such a decoction each time. Is not preferable.

従って、本発明においては、エキスを常法により製剤化した、いわゆるエキス製剤としての防風通聖散がむしろ便宜に使用される。なお、エキス製剤の製法としては、例えば、上記各成分の混合物に対し、約7倍量の水を加え、80°C〜90°C程度で3時間程度撹拌抽出し、温時遠心分離して抽出液を得、これを減圧下に濃縮し、スプレードライ法により乾燥エキスとするか、或いはエキスの濃度を高めた軟エキスに適当な吸着剤(例えば無水ケイ酸、デンプン等)を加えて吸着末とする方法が挙げられる。又、漢方エキス製剤が一般用、医療用のいずれを問わず包含されることは言うまでもない。   Therefore, in the present invention, Fukatsu Sansho-san as a so-called extract preparation in which the extract is formulated by a conventional method is used for convenience. In addition, as a manufacturing method of the extract formulation, for example, about 7 times the amount of water is added to the mixture of the above components, and the mixture is stirred and extracted at about 80 ° C. to 90 ° C. for about 3 hours, and then centrifuged at warm temperature. Obtain an extract and concentrate it under reduced pressure to obtain a dry extract by spray drying, or add a suitable adsorbent (eg silicic anhydride, starch, etc.) to a soft extract with increased extract concentration There is a method to make the end. In addition, it goes without saying that Kampo extract preparations are included regardless of whether they are for general use or for medical use.

本発明において、防風通聖散の1日当たりの投与量は、成書に記載される処方の重量部をg単位とし、容量部をミリリットル単位とした場合に得られるエキス又はエキス製剤の量でよい。従って、市販のエキス製剤の1日量がそのまま本発明における1日量として使用され得る。   In the present invention, the daily dose of Fufutsu Seisaku may be the amount of extract or extract preparation obtained when the weight part of the prescription described in the book is in g units and the volume part is in milliliter units. . Therefore, the daily dose of a commercially available extract preparation can be used as it is as the daily dose in the present invention.

本発明において、コウボク等はその植物の処理物を使用してもよく、処理物としては、例えば乾燥、粉砕、抽出、製剤化したもの、あるいはこれらの操作の幾つかの組み合わせにより得られる、より経口投与に適した形態のものが挙げられる。   In the present invention, a processed product of the plant may be used as the processed product, such as dried, pulverized, extracted, formulated, or some combination of these operations. The form suitable for oral administration is mentioned.

本発明において、防風通聖散やコウボク等の量的関係は、防風通聖散に対しコウボク等の各々が0.5重量%〜25重量%程度であり、好ましくは防風通聖散エキス5.0グラムに対し、コウボク、オウギはその粉末を各0.3グラム、コウジュ、ゴカジン、キジュツ、ケツメイシ、ヒハツはその粉末を各0.5グラム、モクテンリョウ粉末1.0グラムの割合とするのがよい。   In the present invention, the quantitative relationship between Fukatsutsu Seisaku and Koboku is about 0.5% to 25% by weight for each of Kokutoku etc. For 0 grams, Koboku and Ogi should have a ratio of 0.3 grams of powder, and Koju, Gokadine, Kijutsu, Ketsumeishi, and Hibatsu should have a ratio of 0.5 grams of powder and 1.0 grams of Mokten Ryo powder. .

投与に際しては、これらの粉末を個々に投与してもよいが、常法により錠剤、丸剤等の一つにまとめた形態とするのがよい。この為には、モロヘイヤ末及びマンニトール溶液を賦形剤、展着剤として用いる。なお、モロヘイヤは、その粘液多糖類の働きにより食物中の脂肪分粘液質の作用で糞便の腸管通過を助ける物と考えられる。また、モロヘイヤは、色々なビタミンを含むため栄養的にも優れている。   In administration, these powders may be administered individually, but it is preferable that they are combined into one form such as tablets and pills by a conventional method. For this purpose, Morohaya powder and mannitol solution are used as excipients and spreading agents. Morohaya is considered to be a substance that helps faecal passage through the intestinal tract by the action of fat mucus in food due to the action of the mucus polysaccharide. Morohaya is also nutritionally superior because it contains various vitamins.

本発明において、薬剤は、一日当たりの分量を2〜3回に分けて経口投与するのがよく、服用時刻は、特に限定されないが、食前の空腹時が望ましい。   In the present invention, the drug is preferably administered orally in two or three divided doses per day, and the dose time is not particularly limited, but is preferably fasting before meals.

以下、本発明を実施例に基づいて詳細に説明する。   Hereinafter, the present invention will be described in detail based on examples.

防風通聖散エキス(本草製薬K.K販売、以下同様)5.0g、コウボク末、オウギ末(K.K.天海堂販売、以下同様)各0.5g、コウジュ末、ゴカジン末、キジュツ末、ケツメイシ末、ヒハツ末各0.5g、モクテンリョウ末1.0g、モロヘイヤ粉末(K.K.皇漢薬品研究所販売)0.5gの混合物に、20W/v%マンニトール2.5mlを加え、練合し、12個の錠剤を得た。   Fufutsu Seisaku Extract (Honsa Pharmaceutical KK sale, the same applies below) 5.0g, Koboku powder, Ogi powder (KK Tenkaidou sale, same applies below) 0.5g each, Koju powder, gokajin powder, kijutsu powder , Ketsumeishi powder, Hibatsu powder 0.5g each, Mokten Ryo powder 1.0g, Morohaya powder (KK K. Kanghan Pharmaceutical Research Laboratories) 0.5g, add 2.5ml of 20W / v% mannitol and knead 12 tablets were obtained.

本発明の製剤は、一日、2〜3回に分けて経口投与するのがよく、服用時刻は、特に限定されないが、食前が好ましい。   The preparation of the present invention is preferably administered orally in two to three times a day, and the time of taking is not particularly limited, but is preferably before meals.

21才の女性(身長159.0cm、体重84.1kg、体脂肪率48.0%、肥満度51.2%、右足体脂肪率46.9%、左足体脂肪率47.3%、右腕体脂肪率43.9%、左腕体脂肪率45.6%、体幹部体脂肪率49.2%)に防風通聖散エキス顆粒7.5gを一日分とし、これを3回に分けて食前に服用させ、28日間継続させた。なお、この間、食事は特に制限しなかった。その結果、体重、体脂肪率、肥満度とも、実験開始前と何らの変化もなかった。   21-year-old woman (height 159.0 cm, weight 84.1 kg, body fat percentage 48.0%, obesity 51.2%, right leg fat percentage 46.9%, left leg fat percentage 47.3%, right arm body Fat percentage 43.9%, left arm fat percentage 45.6%, trunk body fat percentage 49.2%), and Fengshu Sansho extract granule 7.5g for one day, divided into three times before meal And continued for 28 days. During this period, the meal was not particularly limited. As a result, there was no change in body weight, body fat percentage, and obesity before the start of the experiment.

次いで、同人に、上記実験終了後、直に実施例1と同様にして得た錠剤を一日分とし、これを3回に分けて食前に投与し、11カ月間継続した結果、身長159.0cm、体重56.1kg、体脂肪率29.7%、肥満度0.9%、右足体脂肪率32.2%、左足体脂肪率32.9%、右腕体脂肪率23.9%、左腕体脂肪率25.3%、体幹部体脂肪率28.7%)であった。なお、食事については、防風通聖散エキス顆粒のみの場合と同様、何らの制限もしなかった。   Next, after completing the above experiment, the same tablet as that of Example 1 was given to the same person for one day, and this was divided into three times and administered before meals, and continued for 11 months. 0cm, body weight 56.1kg, body fat percentage 29.7%, obesity level 0.9%, right foot fat percentage 32.2%, left leg fat percentage 32.9%, right arm fat percentage 23.9%, left arm The body fat percentage was 25.3% and the trunk body fat percentage was 28.7%). In addition, about the meal, there was no restriction | limiting similarly to the case of only Fengtsu Seikisan extract granule.

52才の女性(身長148.0cm、体重75.6kg、体脂肪率50.1%、肥満度56.9%、右足体脂肪率47.1%、左足体脂肪率47.8%、右腕体脂肪率47.9%、左腕体脂肪率50.2%、体幹部体脂肪率51.9%)に防風通聖散エキス顆粒7.5gを1日2回に分けて21日間、朝晩、食前に服用させたが、体重、体脂肪率、肥満度とも、何の変化もなかった。   52-year-old woman (height 148.0cm, weight 75.6kg, body fat percentage 50.1%, obesity 56.9%, right foot fat percentage 47.1%, left leg fat percentage 47.8%, right arm body (Fat rate 47.9%, left arm body fat rate 50.2%, trunk body fat rate 51.9%) Fengtsu Sansho extract granule 7.5g twice a day for 21 days, morning and evening, before meals However, there was no change in body weight, body fat percentage, or obesity level.

次いで、同人に、この実験終了後、直に実施例1と同様にして得た錠剤を1日分とし、これを2回に分けて、朝晩、食前に服用させた。なお、この実験においても、食事制限は何ら行わなかった。
57日経過した結果、身長148.0cm、体重65.6kg、体脂肪率44.7%、肥満度35.9%、右足体脂肪率43.6%、左足体脂肪率43.7%、右腕体脂肪率41.2%、左腕体脂肪率43.5%、体幹部体脂肪率45.6%であった。
なお、本草製薬K.K.の防風通聖散エキス顆粒の代わりにカネボウ薬品K.K.の製品を用い、実施例1と同様にして得た錠剤を、上記女性と同様の症状を示す女性患者に投与し、同様の治療効果を得た。
Then, after the end of this experiment, the same person made a tablet obtained in the same manner as in Example 1 for 1 day, divided into 2 portions, and took it in the morning and evening before meals. In this experiment, no dietary restriction was performed.
57 days passed, height 148.0 cm, weight 65.6 kg, body fat percentage 44.7%, obesity 35.9%, right foot fat percentage 43.6%, left leg fat percentage 43.7%, right arm The body fat percentage was 41.2%, the left arm fat percentage was 43.5%, and the trunk fat percentage was 45.6%.
In addition, Honso Pharmaceutical K.K. K. Kanebo Pharmaceutical K. instead of Kyutsutsu Seisaku Extract Granules K. A tablet obtained in the same manner as in Example 1 was administered to a female patient exhibiting the same symptoms as the above-mentioned woman, and the same therapeutic effect was obtained.

48才の女性(身長160.0cm、体重72.1kg、体脂肪率41.5%、肥満度28.0%、右足体脂肪率41.1%、左足体脂肪率42.0%、右腕体脂肪率37.8%、左腕体脂肪率39.2%、体幹部体脂肪率42.0%)に実施例1と同様にして得た錠剤を1日分とし、これを2回に分けて、朝晩、食前に服用させた。なお、この実験においても、食事制限は何ら行わなかった。
12カ月経過した結果、身長160.0cm、体重61.9kg、体脂肪率35.1%、肥満度9.9%、右足体脂肪率36.0%、左足体脂肪率36.9%、右腕体脂肪率31.5%、左腕体脂肪率31.4%、体幹部体脂肪率34.8%であった。
48-year-old woman (height 160.0 cm, weight 72.1 kg, body fat percentage 41.5%, obesity 28.0%, right foot fat percentage 41.1%, left leg fat percentage 42.0%, right arm body (37.8% fat, 39.2% left arm fat percentage, 42.0% trunk fat percentage), and the tablets obtained in the same manner as in Example 1 were divided into two portions. I took them before meals in the morning and evening. In this experiment, no dietary restriction was performed.
After 12 months, the height was 160.0 cm, the body weight was 61.9 kg, the body fat percentage was 35.1%, the obesity level was 9.9%, the right foot fat percentage was 36.0%, the left leg fat percentage was 36.9%, the right arm The body fat percentage was 31.5%, the left arm fat percentage was 31.4%, and the trunk fat percentage was 34.8%.

男性患者に、実施例1と同様にして得た錠剤を1日分とし、これを3回に分けて、毎食前に服用させ、血液生化学検査を行った。実験前の値は、ALP187(100〜350)(カッコ内の数値は基準値、以下同様)、GOT36(8〜40)、GPT70(5〜40)、コリン−E430(190〜430)、γ─GTP35(0〜70)、総コレステロール240(130〜220)、HDL−CHO32(35〜75)、トリグリセライド553(50〜150)、血糖116(60〜109)であった。
実験50日後、ALP157、GOT20、GPT21、コリン−E369、γ─GTP17、総コレステロール142、HDL−CHO45、トリグリセライド146、血糖81に改善した。
A male patient was given a tablet obtained in the same manner as in Example 1 for one day, divided into three doses, taken before each meal, and a blood biochemical test was performed. Values before the experiment are ALP187 (100 to 350) (the values in parentheses are reference values, the same applies hereinafter), GOT36 (8 to 40), GPT70 (5 to 40), choline-E430 (190 to 430), γ GTP35 (0-70), total cholesterol 240 (130-220), HDL-CHO32 (35-75), triglyceride 553 (50-150), blood glucose 116 (60-109).
50 days after the experiment, ALP157, GOT20, GPT21, choline-E369, γ-GTP17, total cholesterol 142, HDL-CHO45, triglyceride 146, and blood glucose 81 were improved.

女性患者に、実施例1と同様にして得た錠剤を1日分とし、これを3回に分けて、毎食前に服用させた。実験前の血液生化学検査値は、GOT60(8〜40)、GPT109(5〜40)、コリン−E522(190〜430)、γ─GTP137(0〜70)、総コレステロール264(130〜220)、HDL−CHO39(35〜75)、トリグリセライド482(50〜150)、血糖121(60〜109)であった。
実験開始3カ月後には、GOT17、GPT18、コリン−E286、γ─GTP21、総コレステロール246、HDL−CHO49、トリグリセライド78、血糖100に改善した。
The female patient was given a tablet obtained in the same manner as in Example 1, and this was divided into three times and taken before each meal. Blood biochemical test values before the experiment were GOT60 (8-40), GPT109 (5-40), choline-E522 (190-430), γ-GTP137 (0-70), total cholesterol 264 (130-220). HDL-CHO39 (35-75), triglyceride 482 (50-150), blood glucose 121 (60-109).
Three months after the start of the experiment, GOT17, GPT18, choline-E286, γ-GTP21, total cholesterol 246, HDL-CHO49, triglyceride 78, and blood glucose 100 were improved.

以上の実験例からも明らかなように、本発明によれば、優れた抗肥満効果を奏し得る。特に本発明においては、単なる体重減少よりも、むしろ体脂肪の改善に効果が認められた。さらに、血清脂質の改善とそれによると考えられる肝臓機能の改善がみられた。   As is clear from the above experimental examples, according to the present invention, an excellent anti-obesity effect can be achieved. In particular, in the present invention, an effect was observed in improving body fat rather than simply losing weight. In addition, serum lipids were improved and liver function was thought to be improved.

なお、本処方の投与は約2年前より行っており、現在迄の延べ投薬患者数はかなりの数に達している。投薬対象としては高脂血症を伴った肥満症が最も多く、他に糖尿病、肝機能障害、高血圧を随伴する肥満症患者であった。
This prescription has been administered for about 2 years, and the total number of patients to date has reached a considerable number. Among the subjects of administration, obesity with hyperlipidemia was the most common, and obesity patients accompanied by diabetes, liver dysfunction, and hypertension were the most common.

Claims (6)

防風通聖散、コウボク末とガジュツ末のいずれか、オウギ末、コウジュ末、ゴカジン末、ケツメイシ末、キジュツ末、ヒハツ末およびモクテンリョウ末を投与することを特徴とする生活習慣病の予防・改善方法。   A method for the prevention and improvement of lifestyle-related diseases characterized by administration of either Fufutsu Seisaku, Koboku powder or Gajutsu powder, Ogi powder, Koju powder, Gokajin powder, Ketsumeishi powder, Kijutsu powder, Hibatsu powder and Mokten Ryo powder . 生活習慣病が、肥満、糖尿病、高止血症である、請求項1記載の生活習慣病の予防・改善方法。   The method for preventing / ameliorating a lifestyle-related disease according to claim 1, wherein the lifestyle-related disease is obesity, diabetes, or hypertension. 投与量が、一日当たり、防風通聖散は漢方処方により定められている一日分の量であり、他の成分のそれぞれは防風通聖散に対して0.5 重量%〜25重量%である、請求項1記載の生活習慣病の予防・改善方法。   Dosage is per day, Fengtsu Sansho is the amount of one day stipulated by Kampo prescription, and each of the other ingredients is 0.5% to 25% by weight with respect to Fukatsu Sanseiku The method for preventing or improving lifestyle-related diseases according to claim 1. 一日当たりの投与量を、2又は3等分割して、朝晩又は朝昼晩の食前に投与する、請求項3記載の生活習慣病の予防・改善方法。   4. The method for preventing and improving lifestyle-related diseases according to claim 3, wherein the daily dose is divided into two or three equal parts and administered before meals in the morning or evening. 防風通聖散、コウボク末とガジュツ末のいずれか、オウギ末、コウジュ末、ゴカジン末、ケツメイシ末、キジュツ末、ヒハツ末及びモクテンリョウ末を含有することを特徴とする生活習慣病の予防・改善剤。   A prophylactic / improving agent for lifestyle-related diseases characterized by containing one of Fufutsu Seisaku, Koboku powder and Gajutsu powder, Ogi powder, Koju powder, Gokajin powder, Ketsumeishi powder, Kijutsu powder, Hibatsu powder and Mokten Ryo powder. . コウボク末とガジュツ末のいずれか、オウギ末、コウジュ末、ゴカジン末、ケツメイシ末、キジュツ末、ヒハツ末及びモクテンリョウ末の含有量は、それぞれ防風通聖散に対して0.5 重量%〜25重量%である、請求項5記載の生活習慣病の予防・改善剤。
The content of either Koboku powder or Gadju powder, Ogi powder, Koju powder, Gokajin powder, Ketsumeishi powder, Kijutsu powder, Hihatsu powder and Mokten Ryo powder is 0.5% to 25% by weight, respectively. The preventive / ameliorating agent for lifestyle-related diseases according to claim 5, which is%.
JP2006103874A 2006-04-05 2006-04-05 Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same Pending JP2007277128A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006103874A JP2007277128A (en) 2006-04-05 2006-04-05 Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006103874A JP2007277128A (en) 2006-04-05 2006-04-05 Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same

Publications (1)

Publication Number Publication Date
JP2007277128A true JP2007277128A (en) 2007-10-25

Family

ID=38678962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006103874A Pending JP2007277128A (en) 2006-04-05 2006-04-05 Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same

Country Status (1)

Country Link
JP (1) JP2007277128A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100857691B1 (en) * 2007-05-31 2008-09-23 한림대학교 산학협력단 Composition for inhibiting development diabetes induced complication containing elsholtzia ciliata extract
WO2009093737A1 (en) * 2008-01-25 2009-07-30 Kobayashi Pharmaceutical Co., Ltd. Anti-obesity pharmaceutical composition
JP2009196996A (en) * 2008-01-25 2009-09-03 Kobayashi Pharmaceut Co Ltd Medicinal composition
JP2009242330A (en) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd Bofutusyosan-blended preparation
JP2009242328A (en) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd Bofutusyosan-blended preparation
JP2009242329A (en) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd Bofutusyosan-blended preparation
JP2013537890A (en) * 2010-09-10 2013-10-07 コリア フード リサーチ インスティチュート Composition for suppressing obesity or lowering blood glucose, comprising Hariguwa and Yokuinin, and use thereof
CN114306373A (en) * 2021-12-31 2022-04-12 广东药科大学 Lipid-lowering composition containing acanthopanax trifoliatus neutral polysaccharide ATP1-1 and preparation method thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100857691B1 (en) * 2007-05-31 2008-09-23 한림대학교 산학협력단 Composition for inhibiting development diabetes induced complication containing elsholtzia ciliata extract
WO2009093737A1 (en) * 2008-01-25 2009-07-30 Kobayashi Pharmaceutical Co., Ltd. Anti-obesity pharmaceutical composition
JP2009196996A (en) * 2008-01-25 2009-09-03 Kobayashi Pharmaceut Co Ltd Medicinal composition
JP2009196990A (en) * 2008-01-25 2009-09-03 Kobayashi Pharmaceut Co Ltd Antiobesitic medicinal composition
JP2009242330A (en) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd Bofutusyosan-blended preparation
JP2009242328A (en) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd Bofutusyosan-blended preparation
JP2009242329A (en) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd Bofutusyosan-blended preparation
JP2013537890A (en) * 2010-09-10 2013-10-07 コリア フード リサーチ インスティチュート Composition for suppressing obesity or lowering blood glucose, comprising Hariguwa and Yokuinin, and use thereof
CN114306373A (en) * 2021-12-31 2022-04-12 广东药科大学 Lipid-lowering composition containing acanthopanax trifoliatus neutral polysaccharide ATP1-1 and preparation method thereof
CN114306373B (en) * 2021-12-31 2022-11-11 广东药科大学 Lipid-lowering composition containing acanthopanax trifoliatus neutral polysaccharide ATP1-1 and preparation method thereof

Similar Documents

Publication Publication Date Title
JP2007277128A (en) Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same
EP1763359B1 (en) Use of pregnane glycosides in the treatment/management of obesity
CN102281886A (en) Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
KR100455222B1 (en) A diet ginseng products and the preparing method thereof
JPH11130686A (en) Prevention and curing of obesity, and anti-obesity agent
CN110898201B (en) A topical Chinese medicinal composition for removing food stagnation in children, and its preparation method
JP2006514041A (en) Composition for suppressing obesity using mixed herbal materials
CN106994141B (en) Traditional Chinese medicine composition for treating constipation and preparation method thereof
CN100450532C (en) Chinese medicinal formulation for treating children&#39;s hyperkinetic syndrome
JP2001086953A (en) Analgesic food for assisting health
CN105343419A (en) Traditional Chinese medicinal pill for invigorating yang and tonifying kidney, and preparation method thereof
CN104888132A (en) Traditional Chinese medicine composition for treatment of chronic gastritis
KR20020074905A (en) Constituents for herbal healthy food containing radish extracts
KR100441308B1 (en) A diet ginseng drink and the preparing method thereof
KR20010009653A (en) Composition for treating sexual dysfunction
CN104815275A (en) Oral medicine for treating pregnancy reaction and preparation method thereof
CN103920023A (en) Traditional Chinese medicine for treating hypertension
CN104800487B (en) It is a kind of to be used to treat traditional Chinese medicinal ointment of chronic constipation and preparation method thereof
JPH06107553A (en) Composition having analgesic function
RU2189243C1 (en) Compositions &#34;ginrosin&#34; showing general tonic and adaptogenic effect
RU2188564C2 (en) Biologically active additive to food for prophylaxis and reduction of weather dependence and sensitivity to sun and geomagnetic storms
CN103071010B (en) Traditional Chinese medicine preparation for treating disorders of gastrointestinal motility
CN106860646B (en) Traditional Chinese medicine composition for treating gastroduodenal ulcer and preparation method thereof
JP2022519320A (en) Compositions and Methods for the Treatment of Constipation and Other Diseases of the Gastrointestinal System
CN106309926A (en) Composition prepared from bee products and medical and edible dual-purpose food and used for treating gastritis and gastric ulcer